Literature DB >> 18230335

Solution NMR studies provide structural basis for endotoxin pattern recognition by the innate immune receptor CD14.

Seth Albright1, Bin Chen, Kristen Holbrook, Nitin U Jain.   

Abstract

CD14 functions as a key pattern recognition receptor for a diverse array of Gram-negative and Gram-positive cell-wall components in the host innate immune response by binding to pathogen-associated molecular patterns (PAMPs) at partially overlapping binding site(s). To determine the potential contribution of CD14 residues in this pattern recognition, we have examined using solution NMR spectroscopy, the binding of three different endotoxin ligands, lipopolysaccharide, lipoteichoic acid, and a PGN-derived compound, muramyl dipeptide to a 15N isotopically labeled 152-residue N-terminal fragment of sCD14 expressed in Pichia pastoris. Mapping of NMR spectral changes upon addition of ligands revealed that the pattern of residues affected by binding of each ligand is partially similar and partially different. This first direct structural observation of the ability of specific residue combinations of CD14 to differentially affect endotoxin binding may help explain the broad specificity of CD14 in ligand recognition and provide a structural basis for pattern recognition. Another interesting finding from the observed spectral changes is that the mode of binding may be dynamically modulated and could provide a mechanism for binding endotoxins with structural diversity through a common binding site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230335      PMCID: PMC2363573          DOI: 10.1016/j.bbrc.2008.01.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors.

Authors:  A Ozinsky; D M Underhill; J D Fontenot; A M Hajjar; K D Smith; C B Wilson; L Schroeder; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  CD14 employs hydrophilic regions to "capture" lipopolysaccharides.

Authors:  M D Cunningham; R A Shapiro; C Seachord; K Ratcliffe; L Cassiano; R P Darveau
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

3.  Soluble CD14 truncated at amino acid 152 binds lipopolysaccharide (LPS) and enables cellular response to LPS.

Authors:  T S Juan; M J Kelley; D A Johnson; L A Busse; E Hailman; S D Wright; H S Lichenstein
Journal:  J Biol Chem       Date:  1995-01-20       Impact factor: 5.157

4.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

5.  Glycosyl-phosphatidylinositol-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin.

Authors:  J D Lee; V Kravchenko; T N Kirkland; J Han; N Mackman; A Moriarty; D Leturcq; P S Tobias; R J Ulevitch
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

6.  Analysis of lipopolysaccharide binding by CD14.

Authors:  T N Kirkland; F Finley; D Leturcq; A Moriarty; J D Lee; R J Ulevitch; P S Tobias
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

7.  Purification and characterization of human soluble CD14 expressed in Pichia pastoris.

Authors:  Shin-ichi Nomura; Kei-ichiro Inamori; Tatsushi Muta; Soh Yamazaki; Yuko Sunakawa; Sadaaki Iwanaga; Koichiro Takeshige
Journal:  Protein Expr Purif       Date:  2003-04       Impact factor: 1.650

8.  CD14: physical properties and identification of an exposed site that is protected by lipopolysaccharide.

Authors:  M D McGinley; L O Narhi; M J Kelley; E Davy; J Robinson; M F Rohde; S D Wright; H S Lichenstein
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

9.  Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures.

Authors:  B Weidemann; H Brade; E T Rietschel; R Dziarski; V Bazil; S Kusumoto; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Soluble CD14 participates in the response of cells to lipopolysaccharide.

Authors:  E A Frey; D S Miller; T G Jahr; A Sundan; V Bazil; T Espevik; B B Finlay; S D Wright
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  2 in total

1.  Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation.

Authors:  Corinna Lau; Kristin S Gunnarsen; Lene S Høydahl; Jan Terje Andersen; Gøril Berntzen; Anne Pharo; Julie K Lindstad; Judith K Ludviksen; Ole-Lars Brekke; Andreas Barratt-Due; Erik Waage Nielsen; Christopher R Stokes; Terje Espevik; Inger Sandlie; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2013-09-23       Impact factor: 5.422

2.  The crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket.

Authors:  Stacy L Kelley; Tiit Lukk; Satish K Nair; Richard I Tapping
Journal:  J Immunol       Date:  2012-12-21       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.